Original Paper

Plasma ET-1 Concentrations Are Elevated in Pregnant Women with Hypertension - Meta-Analysis of Clinical Studies

Yong-Ping Lu^{a,b} Ahmed Abdallah Hasan^{a,c} Shufei Zeng^{a,b,d} Berthold Hocher^{a,d}

^aInstitute of Nutritional Science, University of Potsdam, Potsdam, ^bDepartment of Nephrology, Charité - Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany; ^cDepartment of Biochemistry, Faculty of Pharmacy, Zagazig University, Egypt; ^dDepartment of Embryology, Medical School of the Jinan University, Guangzhou, China

Key Words

Et-1 • Pregnancy • Hypertension • Meta-analysis

Abstract

Background/Aims: The ET system might be involved in the pathogenesis of hypertensive disorders during pregnancy. The objective is to analyse the impact of ET-1 in hypertensive pregnant women by a strict meta-analysis of published human clinical studies. **Methods:** Based on the principle of Cochrane systematic reviews, Cohort studies in PubMed (Medline), Google Scholar and China Biological Medicine Database (CBM-disc) designed to identify the role of endothelin-1 (ET-1) in the pathophysiology of gestational hypertension and preeclampsia were screened. Review Manager Version 5.0 (Rev-Man 5.0) was applied for statistical analysis. Mean difference and 95% confidence interval (CI) were shown in inverse variance (IV) fixed-effects model or IV random-effects model. **Results:** Sixteen published cohort studies including 1739 hypertensive cases and 409 controls were used in the meta-analysis. ET-1 plasma concentrations were higher in hypertensive pregnant women as compared to the controls (mean difference between groups: 19.02 [15.60~22.44], $P < 0.00001$). These findings were driven by severity of hypertension and/or degree of proteinuria. **Conclusion:** Plasma ET-1 concentrations are elevated in hypertensive disorders during human pregnancy. In particular women with preeclampsia (hypertensive pregnant women with proteinuria) have substantially elevated plasma ET-1 concentration as compared to pregnant women with normal blood pressure.

© 2017 The Author(s)
Published by S. Karger AG, Basel

Introduction

Approximately thirty-years ago Hickey *et al.* [1] described an endothelium-derived constricting factor in the supernatant of bovine aortic endothelial cells. This factor was

thought to be a peptide hormone, since trypsin abolished the vasoconstrictive property of this new factor [1]. The molecular structure of this endothelium-derived constricting factor was identified by Yanagisawa *et al.* [2]. It was named endothelin, because it was isolated from the supernatant of porcine aortic endothelial cells. Endothelin produces powerful, very long-lasting constrictions of a range of mammalian blood vessels *in vitro* including human arteries and veins. It also causes long-lasting elevation of blood pressure when injected into rodents [2]. Because of these observations, scientists at this time were of the opinion that this peptide - nowadays called endothelin-1 (ET-1) plays an important role in the pathogenesis of arterial hypertension as well as pregnancy induced hypertension/preeclampsia [3]. It was thus a surprising finding that ET-1 transgenic mice do not develop hypertension. This was first shown by our group in Berlin, Germany [4]. ET-2 overexpressing rats likewise do not develop hypertension [5]. Both rat and mouse ET overexpression models develop chronic kidney disease characterized by renal interstitial fibrosis and glomerulosclerosis in a blood pressure independent manner [4-10]. When going to the original publications, it was always noted that numerically the blood pressure was even somewhat lower in ET-1 transgenic mice as compared to their WT control counterparts. We recently performed a meta-analysis addressing this topic. This meta-analysis provides robust evidence that systemic ET-1 overexpression in mice lowers blood pressure in an age-dependent manner [11]. A subsequent meta-analysis - on the other hand - revealed that ET-1 plasma concentrations are elevated in humans with essential hypertension [12]. Given these contradictory findings in transgenic endothelin rodent models and humans with essential hypertension as well as the initial hypothesis that ET-1 might be involved in the pathogenesis of hypertension during pregnancy, the aim of the current study therefore was to perform a systematic review and meta-analysis of all so far published studies reporting ET-1 plasma concentrations in pregnant women. Hypertensive disorders during pregnancy remains a major cause of maternal morbidity and mortality as well as poor fetal short and long-term outcome [13-17]. Gestational hypertension is a clinical diagnosis defined by the new onset of hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg) at ≥ 20 weeks of gestation in the absence of proteinuria or new signs of end-organ dysfunction [16-19]. Gestational hypertension is considered severe when systolic blood pressure is ≥ 160 mmHg and/or diastolic blood pressure is ≥ 110 mmHg on two consecutive blood pressure measurements at least four hours apart [16-19]. Gestational hypertension is a temporary diagnosis for hypertensive pregnant women who do not meet criteria for preeclampsia. Preeclampsia is diagnosed, if proteinuria or new signs of end-organ dysfunction develop.

Materials and Methods

The meta-analysis was conducted according to principles and methods that we recently published [11, 12, 20, 21].

Search strategy

Two authors screened for clinical studies in PubMed (Medline) and Google Scholar relevant to the topic of ET-1 and hypertension in humans. We included studies published between January 1, 1991 and March 31, 2017. Searching keywords were “endothelin-1”, and “gestational hypertension or preeclampsia”.

Inclusion and exclusion criteria

We screened all published studies in English and Chinese published between January 1990 until June 2017. Inclusion criteria were:

(1) Clear definition of gestational hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg in at least two occasions at least 4-6 h apart after the 20th week of gestational), mild preeclampsia (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg in at

least two measurements. measured on two occasions at least 4-6 h apart after the 20th gestational week, with proteinuria >0.3 g/24h and edema), and severe preeclampsia (systolic blood pressure $\geq$ 160 mmHg and/or diastolic blood pressure $\geq$ 100 mmHg in at least two measurements. measured on two occasions at least 4-6 h apart after the 20th gestational week, gestational hypertension with proteinuria >2.0 g/24h and edema);

(2) no twins pregnancies were allowed

(3) clear information on the study design in particular information on in-and exclusion criteria and maternal baseline characteristics.

We excluded duplicate publications, abstracts only publications, and review articles. Studies without comparison with normotensive pregnant subjects were likewise excluded. If blood sampling was not clearly defined, we also excluded these studies.

Data extraction and quality assessment

Two authors selected relevant articles, abstracted data, and evaluated the quality of enrolled studies independently. Questionable studies were resolved by discussion or consensus based on the views of a third reviewer. We contacted the authors when we encountered information that was unclear or incomplete.

The following data were extracted from the included articles: ET-1 blood concentrations, age. Data were given as mean $\pm$ SD. When data are given as mean and range (a,b), $SD \approx [(b-a)^2 + (a-2m+b)^2/4]^{1/2}/12^{1/2}$ ($n \leq 15$) or $SD \approx (b-a)/4$ ($15 < n \leq 70$) [22]. In the sixteen included papers, ten used ng/L as ET-1 concentration unit, five papers used pg/mL, and one paper used pmol/L. So, we unified the ET-1 concentration unit as ng/L, 1 ng/L ET-1 = 1 pg/mL ET-1 = 2.4919 $\times$ pmol/L ET-1.

Table 1. Characteristics of included studies

Study ID	Variable	Normotensive		Gestational hypertension		Mild preeclampsia		Severe preeclampsia	
		Number	Value	Number	Value	Number	Value	Number	Value
Florijn, 1991	ET-1	25	2.1 $\pm$ 0.53	-	-	25	5.0 $\pm$ 2.6	-	-
Benigni, 1992	ET-1	19	0.48 $\pm$ 0.53	-	-	10	0.40 $\pm$ 0.22	-	-
	Age	19	29.3 $\pm$ 6.1	-	-	10	31.1 $\pm$ 4.1	-	-
Zafirovska, 1999	ET-1	178	37.36 $\pm$ 18.07	79	42.7 $\pm$ 16.43	-	-	-	-
	Age	178	27.6 $\pm$ 5.4	79	28.1 $\pm$ 6.3	-	-	-	-
Slowinski, 2002	ET-1	30	0.44 $\pm$ 0.45	-	-	125	0.75 $\pm$ 1.2	-	-
	Age	30	27.8 $\pm$ 8.2	-	-	125	30.4 $\pm$ 9.1	-	-
Vural, 2002	ET-1	20	30.85 $\pm$ 6.25	-	-	19	37.18 $\pm$ 15.40	-	-
	Age	20	29.2 $\pm$ 6.7	-	-	19	28.37 $\pm$ 5.34	-	-
Zhang, 2005	ET-1	58	21.11 $\pm$ 6.39	60	33.23 $\pm$ 11.80	-	-	-	-
	Age	58	21.11 $\pm$ 6.39	60	33.23 $\pm$ 11.80	-	-	-	-
Lin, 2010	ET-1	42	1.78 $\pm$ 1.33	48	3.67 $\pm$ 2.43	-	-	38	4.83 $\pm$ 2.75
	Age	42	27.3 $\pm$ 3.6	86	-	-	28.6 $\pm$ 4.1	-	-
La, 2011	ET-1	35	68.90 $\pm$ 14.36	-	-	-	-	46	98.24 $\pm$ 45.04
Zhou, 2013	ET-1	40	41.78 $\pm$ 3.48	23	48.53 $\pm$ 3.28	24	61.44 $\pm$ 3.84	23	74.38 $\pm$ 4.03
	Age	40	28.38 $\pm$ 7.48	70	-	-	29.48 $\pm$ 8.43	-	-
Feng, 2013	ET-1	30	95.82 $\pm$ 30.65	28	100.23 $\pm$ 32.83	30	122.42 $\pm$ 27.62	22	142.65 $\pm$ 24.33
	Age	30	27.65 $\pm$ 7.02	80	-	-	25.43 $\pm$ 6.92	-	-
Shi, 2014	ET-1	40	22.13 $\pm$ 4.55	-	-	39	33.41 $\pm$ 5.37	40	41.29 $\pm$ 7.18
	Age	40	28.56 $\pm$ 5.87	-	-	39	28.38 $\pm$ 4.29	40	28.64 $\pm$ 5.12
Zhang, 2014	ET-1	30	29.3 $\pm$ 4.5	-	-	20	45.3 $\pm$ 5.1	16	52.4 $\pm$ 6.1
	Age	30	27.1 $\pm$ 6.3	-	-	20	26.5 $\pm$ 6.7	16	28.1 $\pm$ 6.4
Zhang, 2015	ET-1	40	36.17 $\pm$ 6.28	34	45.83 $\pm$ 9.32	58	62.31 $\pm$ 10.72	38	75.85 $\pm$ 11.52
	Age	40	27.56 $\pm$ 4.31	130	-	-	27.37 $\pm$ 2.87	-	-
Zeng, 2015	ET-1	200	46.75 $\pm$ 4.97	-	-	127	65.83 $\pm$ 5.56	102	79.34 $\pm$ 5.08
	Age	200	27.9 $\pm$ 1.7	-	-	239	-	26.5 $\pm$ 2.2	-
Lu, 2016	ET-1	30	53.0 $\pm$ 2.90	-	-	30	73.0 $\pm$ 6.2	30	85.7 $\pm$ 5.1
	Age	30	29.6 $\pm$ 2.0	-	-	30	29.1 $\pm$ 2.4	30	30.0 $\pm$ 20.0
Lv, 2016	ET-1	120	58.26 $\pm$ 7.22	53	82.17 $\pm$ 19.63	43	108.29 $\pm$ 28.31	24	124.24 $\pm$ 36.84
	Age	120	28.36 $\pm$ 4.23	120	-	-	29.12 $\pm$ 3.84	-	-

Statistical processing

Statistical analyses were conducted by Review Manager Version 5.0 (Rev-Man 5.0) software, devised by Co-chrane Collaboration as described earlier [11, 12, 18]. Heterogeneity was assessed by P value and I^2 . If there was no heterogeneity ($P \geq 0.1$, $I^2 \leq 50\%$), we used the IV fixed-effects model. If there was high heterogeneity ($P < 0.1$, $I^2 > 50\%$), we chose IV random-effects model. Binary outcomes were expressed as the risk ratio (RR) with 95%CI. Continuous variables were expressed as mean difference (MD) with 95% CI. In test for overall effect, the $P \leq 0.05$ was considered statistically significant.

We performed also a subgroup analysis of the hypertensive patients. subgroup 1, gestational hypertension; subgroup 2 mean SBP > 160 mmHg; subgroup 3 mean SBP unclear. A comparable classification was used for diastolic blood pressure subgroups: subgroup 1, gestational hypertension; subgroup 2, mild preeclampsia; subgroup 3, severe preeclampsia. For the data of age, some papers combined gestational hypertension, mild preeclampsia, and severe preeclampsia as hypertension disorder complicating pregnancy. In this case, hypertension disorder complicating pregnancy as subgroup 4.

Results

Basic information

Based on the principle of Cochrane systematic reviews, and the inclusion and exclusion criteria of our meta-analysis, Sixteen [23-38] published cohort studies were included in

Fig. 1. Flow chart of searching article, eliminating the unmatched articles and include articles.

the present meta-analysis (1739 patients in the hypertensive group, 409 controls in the normotensive group). A more detailed description of the clinical characteristics of the included studies is given in Table 1. The study design/flow chart is given in figure 1.

ET-1 and gestational hypertension

Sixteen studies [23-38] reporting data on ET-1 and gestational hypertension and/or preeclampsia could be included into the meta-analysis.

The overall effect of the sixteen studies [23-38] showed that hypertensive pregnant women had higher ET-1 plasma concentrations than normotensive controls (mean difference: 19.02 ng/L, 95%CI [15.60~22.44], $P < 0.00001$, with high heterogeneity ($P < 0.00001$, $I^2 = 100\%$), Fig. 2). A subgroups analysis according to severity of hypertension and/or proteinuria, in the gestational hypertension group revealed that hypertensive pregnant women with no proteinuria (mean difference 9.27 ng/L, 95%CI [4.72~13.82], $P < 0.0001$, with high heterogeneity ($P < 0.00001$, $I^2 = 95\%$), Figure2), mild preeclampsia (mean difference 14.94 ng/L, 95%CI [11.52~18.36], $P < 0.00001$, with high heterogeneity ($P < 0.00001$, $I^2 = 99\%$), Figure2) as well as severe preeclampsia (mean difference 31.74 ng/L, 95%CI [20.98~42.50], $P < 0.00001$, with high heterogeneity ($P < 0.00001$, $I^2 = 100\%$),

Fig. 2. Forrest blot of studies analyzing ET-1 serum concentrations in normotensive and hypertensive pregnant women.

Figure 2) had higher ET-1 level than normotensive pregnant women. The age of the pregnant mothers had no impact on blood ET-1 concentration in normal and hypertensive pregnancy. Taken together, pregnant women with severe hypertension and proteinuria have higher ET-1 concentration among pregnant women with hypertension.

Discussion

The current meta-analysis revealed that plasma ET-1 concentrations are elevated in hypertensive disorders during human pregnancy. In particular women with preeclampsia (hypertensive pregnant women with proteinuria) have substantially elevated plasma ET-1 concentration as compared to pregnant women with normal blood pressure. Comparing the current study results with a recent meta-analysis in non-pregnant hypertensive patients [12], it became obvious that the ET-1 elevation is much more pronounced in hypertensive pregnant women as compared to hypertensive non-pregnant patients. Our data might suggest that ET-1 play a causal role in humans in the pathogenesis of pregnancy related hypertensive diseases.

Whole genome arrays failed so far to demonstrate a significant association between SNPs in genes of the ET system and hypertension during human pregnancy [39]. It should be taken into account that the studies investigating the genetic contributions for pregnancy-induced hypertension and preeclampsia are still limited. Only a few genetic variations were reported to be possibly associated with higher risk of pregnancy-induced hypertension and/or preeclampsia. A genome-wide association study identified a maternal copy-number deletion in the *PSG11* gene to be enriched among preeclampsia patients [40]. Another study reported that angiotensin II type 1 receptor gene *A1166C* polymorphism could be a predisposing factor for pregnancy-induced hypertension [41]. In addition, *NOS3 T-786C* SNP was reported to be associated with the occurrence of preeclampsia and its complications in a small study [42]. This is of particular interest with regard to the topic of our meta-analysis, since the ETB receptor on endothelial cells is a known activator of the endothelial NO synthase [3]. However, there – as stated above – was no signal for any component of the ET system in any genetic study in this particular field so far. Definitive answers may come from the InterPregGen study, the largest genome-wide association study of maternal and fetal genes conducted in Europe, Asia, and South America to screen for genetic risks of preeclampsia. The results of this study are awaited with interest [43].

An alternative hypothesis that might explain our findings would be that yet unknown environmental stimuli during human pregnancy might triggers epigenetic alterations of the human placenta or the vascular system including kidneys of the pregnant women [44-49] leading to an activation of the ET system in hypertensive pregnant women. An involvement of epigenetic mechanisms in the activation of the ET system has been described for diseases such as leukemia [50-53], cardiomyocyte terminal differentiation in the developing heart [54]. These studies in combination with our meta-analysis indicating that the ET system is activated in a disease degree dependent manner in human pregnancy hypertension and the fact that there is no evidence of a genetic association of pregnancy induced hypertension and an activation of the ET system in humans should stimulate researchers to test the potential enrolments of epigenetic mechanisms in human hypertensive pregnancy diseases explaining the activation of the ET system in these diseases.

Endothelin receptor antagonists have been investigated in animal models of hypertension and also in human clinical trials in patients with essential hypertension. This treatment option, however, is not a feasible approach in human pregnancy given the embryo-toxic side effects of endothelin receptor antagonists. Similar effects on embryonic development were also observed in various gene knockout animal models of the ET system [3, 55, 56]. It is of note in this context that ECE/NEP inhibitors [57, 58] – pharmacological agents blocking the conversion of big ET-1 to ET-1 – not to have these embryo-toxic effects [55] and thus

might offer a therapeutic approach for hypertensive diseases during pregnancy. However, this requires very carefully conducted preclinical and clinical studies focusing in particular on safety.

Conclusion

Our meta-analysis clearly demonstrated an activation of the ET system in human hypertensive diseases during pregnancy. The underlying mechanisms are unknown so far. An association of genetic variations of the ET system with pregnancy hypertension was not seen in any of the genome wide association studies addressing this topic. Either epigenetic mechanisms or simply endothelial cell damage due to high blood pressure might be at least partially responsible for increased plasma ET-1 concentrations in human hypertensive diseases during pregnancy.

Disclosure statement

No competing Disclosure Statement for any of the authors.

References

- 1 Hickey KA, Rubanyi G, Paul RJ, Highsmith RF: Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. *Am J Physiol* 1985;248:C550-C556.
- 2 Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 1988;332:411-415.
- 3 Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ: Endothelin. *Pharmacol Rev* 2016;68:357-418.
- 4 Hofer B, Thöne-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer HH, Schleuning WD, Theuring F: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. *J Clin Invest* 1997;99:1380-1389.
- 5 Hofer B, Liefeldt L, Thöne-Reineke C, Orzechowski HD, Distler A, Bauer C, Paul M: Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. *Hypertension* 1996;28:196-201.
- 6 Shindo T, Kurihara H, Maemura K, Kurihara Y, Ueda O, Suzuki H, Kuwaki T, Ju KH, Wang Y, Ebihara A, Nishimatsu H, Moriyama N, Fukuda M, Akimoto Y, Hirano H, Morita H, Kumada M, Yazaki Y, Nagai R, Kimura K: Renal damage and salt-dependent hypertension in aged transgenic mice overexpressing endothelin-1. *J Mol Med (Berl)* 2002;80:105-116.
- 7 Ong AC, von Websky K, Hofer B: Endothelin and tubulointerstitial renal disease. *Semin Nephrol* 2015;35:197-207.
- 8 Tsuprykov O, Chaykovska L, Kretschmer A, Stasch JP, Pfab T, Krause-Relle K, Reichetzeder C, Kalk P, Adamski J, Hofer B: Endothelin-1 Overexpression Improves Renal Function in eNOS Knockout Mice. *Cell Physiol Biochem* 2015;37:1474-90.
- 9 Vignon-Zellweger N, Relle K, Kienlen E, Alter M, Seider P, Sharkovska J, Heiden S, Kalk P, Schwab K, Albrecht-Küpper B, Theuring F, Stasch JP, Hofer B: Endothelin-1 overexpression restores diastolic function in eNOS knockout mice. *J Hypertens* 2011;29:961-970.
- 10 Chang YK, Choi H, Jeong JY, Na KR, Lee KW, Choi DE: Co-inhibition of Angiotensin II Receptor and Endothelin-1 Attenuates Renal Injury in Unilateral Ureteral Obstructed Mice. *Kidney Blood Press Res* 2016;41:450-459.

- 11 Lu YP, Tsuprykov O, Vignon-Zellweger N, Heiden S, Hoher B: Global Overexpression of ET-1 Decreases Blood Pressure - A Systematic Review and Meta-Analysis of ET-1 Transgenic Mice. *Kidney Blood Press Res* 2016;41:770-780.
- 12 Xu M, Lu YP, Hasan AA, Hoher B: Plasma ET-1 Concentrations are Elevated in Patients with Hypertension - Meta-Analysis of Clinical Studies. *Kidney Blood Press Res* 2017;42:304-313.
- 13 Li J, Chen YP, Dong YP, Yu CH, Lu YP, Xiao XM, Hoher B: The impact of umbilical blood flow regulation on fetal development differs in diabetic and non-diabetic pregnancy. *Kidney Blood Press Res* 2014;39:369-377.
- 14 Chen YP, Lu YP, Li J, Liu ZW, Chen WJ, Liang XJ, Chen X, Wen WR, Xiao XM, Reichetzeder C, Hoher B: Fetal and maternal angiotensin (1-7) are associated with preterm birth. *J Hypertens* 2014;32:1833-1841.
- 15 Hoher B, Chen YP, Schlemm L, Burdack A, Li J, Halle H, Pfab T, Kalk P, Lang F, Godes M: Fetal sex determines the impact of maternal PROGINS progesterone receptor polymorphism on maternal physiology during pregnancy. *Pharmacogenet Genomics* 2009;19:710-718.
- 16 American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy: Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol* 2013; 122:1122-1131.
- 17 Sibai BM: Diagnosis and management of gestational hypertension and preeclampsia. *Obstet Gynecol* 2003; 102:181-19.
- 18 Hauth JC, Ewell MG, Levine RJ, Esterlitz JR, Sibai B, Curet LB, Catalano PM, Morris CD: Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. *Obstet Gynecol* 2000;95:24-28.
- 19 Buchbinder A, Sibai BM, Caritis S, Macpherson C, Hauth J, Lindheimer MD, Klebanoff M, Vandersten P, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units: Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. *Am J Obstet Gynecol* 2002;186:66-71.
- 20 He J, Liu ZW, Lu YP, Li TY, Liang XJ, Arck PC, Huang SM, Hoher B, Chen YP: A Systematic Review and Meta-Analysis of Influenza A Virus Infection During Pregnancy Associated with an Increased Risk for Stillbirth and Low Birth Weight. *Kidney Blood Press Res* 2017;42:232-243.
- 21 Hoher B, Adamski J: Metabolomics for clinical use and research in chronic kidney disease. *Nat Rev Nephrol* 2017;13:269-284.
- 22 Wan X, Wang W, Liu J, Tong T: Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014;14:135.
- 23 Florijn KW, Derkx FH, Visser W, Hofman JA, Rosmalen FM, Wallenburg HC, Schalekamp MA: Plasma immunoreactive endothelin-1 in pregnant women with and without pre-eclampsia. *J Cardiovasc Pharmacol* 1991;17 Suppl 7:S446-S448.
- 24 Benigni A, Orsio S, Gaspari F, Frusca T, Amuso G, Remuzzi G: Evidence against a pathogenetic role for endothelin in pre-eclampsia. *Br J Obstet Gynaecol* 1992;99:798-802.
- 25 Zafirovska KG, Maleska VT, Bogdanovska SV, Lozance LA, Masin-Paneva J, Gerasimovska BD: Plasma human atrial natriuretic peptide, endothelin-1, aldosterone and plasma-renin activity in pregnancy-induced hypertension. *J Hypertens* 1999;17:1317-1322.
- 26 Slowinski T, Neumayer HH, Stolze T, Gossing G, Halle H, Hoher B: Endothelin system in normal and hypertensive pregnancy. *Clin Sci (Lond)*. 2002;103 Suppl 48:446S-449S.
- 27 Vural P: Nitric oxide/endothelin-1 in preeclampsia. *Clin Chim Acta* 2002;317:65-70.
- 28 Zhang J, Yu YH: Levels of endothelin and nitric oxide and clinical sense in patients with hypertensive disorder complicating pregnancy. *Chinese Primary Health Care* 2005; 19:82-83
- 29 Lin TY: Levels and clinical significance of serum urotensin II, NO and ET - 1 in patients with hypertensive disorder. *Journal of Guangdong Medical College* 2010; 28:380-381.
- 30 La XL, Zhu QY, Wang DM: Correlation analyses between humoral factors and cytokines in severe preeclampsia patients. *China Journal of Modern Medicine* 2011;21:4501-4505
- 31 Zhou XP: The study of the level and relativity of serum CRP, ET-1 and NO for hypertensive disorder complicating pregnancy. *China Modern Doctor* 2013;51:25-27
- 32 Feng LP, Li JP, Wu LL, Wang HH, Chen M, Gao YM: Clinical significance and changes of serum TNF- α , IL-6 and ET levels in patients with hypertensive disorder in pregnancy. *Hainan Med J* 2013;24:705-707

- 33 Shi XF, Zhou SQ, Xu CL: Changes of serum endothelin, D - dimer and leptin levels in patients with preeclampsia. *Prevention and Treatment of Cardio-Cerebral-Vascular Disease* 2014;8:307-309
- 34 Zhang Y, Li P: Changes and clinical implications of plasma level of endothelin and atrial natriuretic peptide in pregnant women with preeclampsia. *China Medical Herald* 2014;11:155-158
- 35 Zhang LY, Liu YP, Yan Y: Significance of UTRF, ET-1 and CysC in pregnancy-induced hypertension patients with renal impairment. *J Trop Med* 2015;15:1618-1621.
- 36 Zeng Y, Li M, Chen Y, Wang S: Homocysteine, endothelin-1 and nitric oxide in patients with hypertensive disorders complicating pregnancy. *Int J Clin Exp Pathol* 2015 Nov 1;8:15275-15279.
- 37 Lu YH, Han LJ, Zhang L, Ni SN, Tian QY: Analysis of the correlation of serum free calcium prostaglandin E and plasma endothelin in pregnant with different degrees of hypertensive disorder. *Hebei Medical Journal* 2016;38:1057-1059.
- 38 Lv XF, Yang J, He XG: Levels of serum VEGF, ET-1 in patients with hypertension disorder complicating pregnancy and relevant factors. *J Med Theor & Prac* 2016; 29:1004-1005
- 39 Rossi GP, Pitter G: Genetic variation in the endothelin system: do polymorphisms affect the therapeutic strategies? *Ann N Y Acad Sci* 2006;1069:34-50.
- 40 Zhao L, Triche EW, Walsh KM, Bracken MB, Saftlas AF, Hoh J, Dewan AT: Genome-wide association study identifies a maternal copy-number deletion in PSG11 enriched among preeclampsia patients. *BMC Pregnancy Childbirth* 2012;12:61.
- 41 Nałogowska-Głońska K, Łacka BI, Zychma MJ, Grzeszczak W, Zukowska-Szczechowska E, Poreba R, Michalski B, Kniazewski B, Rzempełuch J; PIH Study Group: Angiotensin II type 1 receptor gene A1166C polymorphism is associated with the increased risk of pregnancy-induced hypertension. *Med Sci Monit* 2000;6:523-529.
- 42 Leonardo DP, Albuquerque DM, Lanaro C, Baptista LC, Cecatti JG, Surita FG, Parpinelli MA, Costa FF, Franco-Penteado CF, Fertrin KY, Costa ML: Association of Nitric Oxide Synthase and Matrix Metalloprotease Single Nucleotide Polymorphisms with Preeclampsia and Its Complications. *PLoS One* 2015;10:e0136693.
- 43 Morgan L, McGinnis R, Steinthorsdottir V, Svyatova G, Zakhidova N, Lee WK, Iversen AC, Magnus P, Walker J, Casas JP, Sultanov S, Laivuori H: InterPregGen: genetic studies of pre-eclampsia in three continents. *Nor Epidemiol* 2014;24:141-146.
- 44 Reichetzeder C, Dwi Putra SE, Li J, Hoher B: Developmental Origins of Disease - Crisis Precipitates Change. *Cell Physiol Biochem* 2016;39:919-938
- 45 Reichetzeder C, Dwi Putra SE, Pfab T, Slowinski T, Neuber C, Kleuser B, Hoher B: Increased global placental DNA methylation levels are associated with gestational diabetes. *Clin Epigenetics* 2016;8:82
- 46 Li J, Tsuprykov O, Yang X, Hoher B: Paternal programming of offspring cardiometabolic diseases in later life. *J Hypertens* 2016 Nov;34(11):2111-26
- 47 Hoher B, Haumann H, Rahnenführer J, Reichetzeder C, Kalk P, Pfab T, Tsuprykov O, Winter S, Hofmann U, Li J, Püschel GP, Lang F, Schuppan D, Schwab M, Schaeffeler E: Maternal eNOS deficiency determines a fatty liver phenotype of the offspring in a sex dependent manner. *Epigenetics* 2016;11:539-552
- 48 Dwi Putra SE, Neuber C, Reichetzeder C, Hoher B, Kleuser B: Analysis of genomic DNA methylation levels in human placenta using liquid chromatography-electrospray ionization tandem mass spectrometry. *Cell Physiol Biochem* 2014;33:945-952
- 49 Stow LR, Jacobs ME, Wingo CS, Cain BD: Endothelin-1 gene regulation. *FASEB J* 2011;25:16-28.
- 50 Yang Y, Chen D, Yuan Z, Fang F, Cheng X, Xia J, Fang M, Xu Y, Gao Y: Megakaryocytic leukemia 1 (MKL1) ties the epigenetic machinery to hypoxia-induced transactivation of endothelin-1. *Nucleic Acids Res* 2013;41:6005-6017
- 51 Martinelli S, Maffei R, Fiorcari S, Quadrelli C, Zucchini P, Benatti S, Potenza L, Luppi M, Marasca R: The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli. *Leuk Res* 2017;54:17-24
- 52 Wang R, Löhr CV, Fischer K, Dashwood WM, Greenwood JA, Ho E, Williams DE, Ashktorab H, Dashwood MR, Dashwood RH: Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer. *Int J Cancer* 2013;132:1004-1012
- 53 Yang Q, Sun M, Ramchandran R, Raj JU: IGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension: Role of epigenetic regulation. *Vascul Pharmacol* 2015;73:20-31.

- 54 Paradis A, Xiao D, Zhou J, Zhang L: Endothelin-1 promotes cardiomyocyte terminal differentiation in the developing heart via heightened DNA methylation. *Int J Med Sci* 2014;11:373-380.
- 55 Reichetzeder C, Tsuprykov O, Hoher B: Endothelin receptor antagonists in clinical research--lessons learned from preclinical and clinical kidney studies. *Life Sci* 2014;118:141-148
- 56 von Websky K, Heiden S, Pfab T, Hoher B: Pathophysiology of the endothelin system - lessons from genetically manipulated animal models. *Eur J Med Res* 2009;14:1-6.
- 57 Kalk P, Sharkovska Y, Kashina E, von Websky K, Relle K, Pfab T, Alter M, Guillaume P, Provost D, Hoffmann K, Fischer Y, Hoher B: Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. *Hypertension* 2011;57:755-763
- 58 Sharkovska Y, Kalk P, von Websky K, Relle K, Pfab T, Alter M, Fischer Y, Hoher B: Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. *Clin Lab* 2011;57:507-515.